Amended Quarterly Report (10-q/a)

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q/A

(Mark One)

 

[X]	Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended June 30, 2016
[  ]	Transition Report under Section 13 or 15(d) of the Exchange Act

 

For the transition period from __________ to __________

 

Commission file number:  333-147193

 

FluoroPharma Medical, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada		20-8325616
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

 

8 Hillside Avenue, Suite 108 Montclair, NJ		07042
(Address of principal executive offices)		(Zip Code)

 

[phone]

(Registrant’s telephone number, including area code)

 

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes [X]   No [   ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files.  Yes [X]   No [   ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer	[   ]		Accelerated filer	[   ]
Non-accelerated filer	[   ]		Smaller reporting company	[X]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes [   ]   No [X]

 

As of August 14, 2016, there were 33,756,772 shares of $0.001 par value common stock issued and outstanding.

 

 

Table of Contents

 

 

FORM 10-Q

 

FluoroPharma Medical, Inc.

 

I NDEX

 

			Page
Explanatory Note			2
PART II  - OTHER INFORMATION
Item 6. Exhibits			2
Signatures			3
Exhibit Index			4

 

 

-i-

Table of Contents

 

 

EXPLANATORY N OTE

This amended quarterly report on Form 10-Q/A is being filed solely for the purpose of notating that confidential treatment was requested as to certain portions of Exhibit 10.1 and 10.2 in connection with a pending application for confidential treatment. Exhibit 10.1 and 10.2 were originally filed with FluoroPharma Medical, Inc.’s quarterly report on Form 10-Q on August 15, 2016 with certain redactions. FluoroPharma Medical, Inc. has made no further change to the previously filed quarterly report.

 

 

-1-

Table of Contents

 

 

PART II - OTHER INFORMATION

 

Item 6.  E xhibits

 

Copies of the following documents are included as exhibits to this report pursuant to Item 601 of Regulation S-K.

 

Exhibit No.		Title of Document
10.1		Amendment to License Agreement (number A220395.01) dated as of June 1, 2016 between the Company and the General Hospital Corporation, d/b/a Massachusetts General Hospital**
10.2		Amendment to License Agreement (number A220396.01) dates as of June 1, 2016 between the Company and the General Hospital Corporation, d/b/a Massachusetts General Hospital**
31.1		Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification of the Chief Executive Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002***
32.2		Certification of the Chief Financial Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002***
101.INS		XBRL Instance Document*
101.SCH		XBRL Schema Document*
101.CAL		XBRL Calculation Linkbase Document*
101.LAB		XBRL Label Linkbase Document*
101.PRE		XBRL Presentation Linkbase Document*
101.DEF		XBRL Definition Linkbase Document*

 

* Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability.

 

** Previously filed and Confidential Treatment requested as to certain portions of this Exhibit.

 

*** Previously filed.

 

-2-

Table of Contents

 

 

S IGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

	FluoroPharma Medical, Inc.
Date:  December 15, 2016	/s/ Thomas H. Tulip
	Thomas H. Tulip, Ph.D.
	President and Chief Executive Officer (Principal Executive Officer)
Date: December 15, 2016	/s/ Tamara Rhein
	Tamara Rhein
	Chief Financial Officer (Principal Financial and Accounting Officer)

 

 

 

-3-

Table of Contents

 

 

EXHIBIT I NDEX

 

Exhibit No.		Title of Document
10.1		Amendment to License Agreement (number A220395.01) dated as of June 1, 2016 between the Company and the General Hospital Corporation, d/b/a Massachusetts General Hospital**
10.2		Amendment to License Agreement (number A220396.01) dates as of June 1, 2016 between the Company and the General Hospital Corporation, d/b/a Massachusetts General Hospital**
31.1		Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification of the Chief Executive Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002***
32.2		Certification of the Chief Financial Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002***
101.INS		XBRL Instance Document*
101.SCH		XBRL Schema Document*
101.CAL		XBRL Calculation Linkbase Document*
101.LAB		XBRL Label Linkbase Document*
101.PRE		XBRL Presentation Linkbase Document*
101.DEF		XBRL Definition Linkbase Document*

 

* Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability.

** Previously filed and Confidential treatment requested as to certain portions of this Exhibit

*** Previously filed

 

-4-